WO2002024203A3 - Controlled release formulations for oral administration - Google Patents

Controlled release formulations for oral administration Download PDF

Info

Publication number
WO2002024203A3
WO2002024203A3 PCT/IB2001/001743 IB0101743W WO0224203A3 WO 2002024203 A3 WO2002024203 A3 WO 2002024203A3 IB 0101743 W IB0101743 W IB 0101743W WO 0224203 A3 WO0224203 A3 WO 0224203A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
oral administration
release formulations
pharmaceutically
composition
Prior art date
Application number
PCT/IB2001/001743
Other languages
French (fr)
Other versions
WO2002024203A2 (en
Inventor
Narayanan Badri Vishwanathan
Rajeev S Raghuvanshi
Gour Mukherji
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Narayanan Badri Vishwanathan
Rajeev S Raghuvanshi
Gour Mukherji
Ashok Rampal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN856DE2000 external-priority patent/IN192864B/en
Application filed by Ranbaxy Lab Ltd, Narayanan Badri Vishwanathan, Rajeev S Raghuvanshi, Gour Mukherji, Ashok Rampal filed Critical Ranbaxy Lab Ltd
Priority to AU2001287977A priority Critical patent/AU2001287977A1/en
Priority to KR10-2003-7004205A priority patent/KR20030048410A/en
Priority to BR0114100-7A priority patent/BR0114100A/en
Priority to EP01967605A priority patent/EP1322313A2/en
Priority to APAP/P/2003/002763A priority patent/AP2003002763A0/en
Priority to MXPA03002569A priority patent/MXPA03002569A/en
Publication of WO2002024203A2 publication Critical patent/WO2002024203A2/en
Publication of WO2002024203A3 publication Critical patent/WO2002024203A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition in the form of an oral controlled release solid dosage form comprising an effective amount of drug, or its pharmaceutically acceptable salts. It also relates to a pharmaceutically composition that is suitable for once-a-day dosing regimen.
PCT/IB2001/001743 2000-09-22 2001-09-22 Controlled release formulations for oral administration WO2002024203A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2001287977A AU2001287977A1 (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration
KR10-2003-7004205A KR20030048410A (en) 2000-09-22 2001-09-22 Controlled release formulation for oral administration
BR0114100-7A BR0114100A (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration
EP01967605A EP1322313A2 (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration
APAP/P/2003/002763A AP2003002763A0 (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration
MXPA03002569A MXPA03002569A (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN856DE2000 IN192864B (en) 2000-09-22 2000-09-22
IN856/DEL/2000 2000-09-22
IN881DE2001 2001-08-24
IN881/DEL/2001 2001-08-24

Publications (2)

Publication Number Publication Date
WO2002024203A2 WO2002024203A2 (en) 2002-03-28
WO2002024203A3 true WO2002024203A3 (en) 2002-11-07

Family

ID=26324883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001743 WO2002024203A2 (en) 2000-09-22 2001-09-22 Controlled release formulations for oral administration

Country Status (9)

Country Link
US (1) US20020119192A1 (en)
EP (1) EP1322313A2 (en)
KR (1) KR20030048410A (en)
CN (1) CN1471398A (en)
AP (1) AP2003002763A0 (en)
AU (1) AU2001287977A1 (en)
BR (1) BR0114100A (en)
MX (1) MXPA03002569A (en)
WO (1) WO2002024203A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684667A (en) * 2002-08-02 2005-10-19 兰贝克赛实验室有限公司 Storage stable tablets of fosinopril sodium
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004096182A1 (en) * 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Extended release matrix tablets of carvedilol
US8469036B2 (en) 2003-11-07 2013-06-25 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
WO2005094793A1 (en) 2004-03-29 2005-10-13 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for preparing a solid pharmaceutical composition
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
US20060045911A1 (en) * 2004-08-27 2006-03-02 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical formulations
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
WO2009000286A1 (en) * 2007-06-25 2008-12-31 Parmatheen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
US20120027855A1 (en) * 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
CA2733787C (en) * 2008-08-15 2016-09-06 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
US9622977B2 (en) * 2008-10-08 2017-04-18 Bioplus Life Sciences Pvt, Ltd. Sustained release drug delivery system
WO2010106555A2 (en) * 2009-03-17 2010-09-23 Shantilal, Doshi, Bimalkumar Directly compressible pre-granulated cellulose ether polymer and process for preparing the same
JP2013519726A (en) 2010-02-17 2013-05-30 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド How to treat conditions sensitive to baclofen therapy
MX2015001751A (en) 2012-08-07 2015-11-13 Topgenix Inc Topical composition comprising transformed bacteria expressing a compound of interest.
BR112017013598A2 (en) * 2014-12-23 2018-03-06 Fmc Corp enteric film coating compositions, coating method, and coated forms
US11324774B2 (en) * 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
CN110840866A (en) * 2018-08-20 2020-02-28 成都新睿泰康科技有限公司 Asarin pharmaceutical composition and application thereof in preventing and treating neurodegenerative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035418A2 (en) * 1998-12-18 2000-06-22 Bayer Corporation Chewable drug delivery system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772470A (en) * 1985-04-27 1988-09-20 Nitto Electric Industrial Co., Ltd. Oral bandage and oral preparations
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
US5498422A (en) * 1991-04-08 1996-03-12 Nippon Shinyaku Company Limited Sustained release capsule
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035418A2 (en) * 1998-12-18 2000-06-22 Bayer Corporation Chewable drug delivery system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WANG, XIAOMIN ET AL: "Preparation of compound gel containing ofloxacin and metronidazole and its quality control", XP002204232, retrieved from STN Database accession no. 130:213565 CA *
HUAXI YAOXUE ZAZHI (1998), 13(3), 185-187, 1998 *

Also Published As

Publication number Publication date
BR0114100A (en) 2003-10-21
EP1322313A2 (en) 2003-07-02
MXPA03002569A (en) 2003-10-14
CN1471398A (en) 2004-01-28
AP2003002763A0 (en) 2003-03-31
WO2002024203A2 (en) 2002-03-28
US20020119192A1 (en) 2002-08-29
AU2001287977A1 (en) 2002-04-02
KR20030048410A (en) 2003-06-19

Similar Documents

Publication Publication Date Title
WO2002024203A3 (en) Controlled release formulations for oral administration
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
WO2004069198A3 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
HK1096034A1 (en) A solid dosage form comprising a fibrate
WO2001022791A8 (en) Controlled release compositions comprising nimesulide
BRPI0015567B8 (en) compound, pharmaceutical composition, dosage unit form, use of the pharmaceutical composition and method for preparing a pharmaceutical composition
WO2001041770A3 (en) Nanoparticulate eplerenone compositions
JO2555B1 (en) Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent
WO2003045437A8 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
EP0966966A3 (en) Nefazodone dosage form
NO20030897D0 (en) Process for the preparation of pharmaceutical compositions for use with wet gelatin formulations
WO2000078294A3 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
ATE287264T1 (en) ORAL MEDICINAL PRODUCTS CONTAINING BUPRENORPHINE
HUP0004966A3 (en) Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine
BR0013719A (en) Controlled-release oral dosage, suitable for oral administration
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
ATE401075T1 (en) MEDICINAL PRODUCT CONTAINING CYTISINE
WO2005004860A3 (en) Novel solid pharmaceutical composition comprising amisulpride
WO2000048445A3 (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
HUP0203148A2 (en) Orally distintegrating composition comprising mirtazapine
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
BR0014440A (en) Oral controlled release formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1020037004205

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002569

Country of ref document: MX

Ref document number: 2001967605

Country of ref document: EP

Ref document number: 1200300281

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: AP/P/2003/002763

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 018181120

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037004205

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001967605

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWR Wipo information: refused in national office

Ref document number: 2001967605

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001967605

Country of ref document: EP